A Randomized, Double-blind, Placebo-controlled, Parallel-designed Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of MEDI5884 in Subjects With Stable Coronary Heart Disease
Phase of Trial: Phase II
Latest Information Update: 15 Feb 2018
At a glance
- Drugs MEDI 5884 (Primary)
- Indications Coronary artery disease
- Focus Adverse reactions
- Sponsors MedImmune
- 08 Jan 2018 Planned End Date changed from 27 Dec 2018 to 2 Jan 2019.
- 08 Jan 2018 Planned primary completion date changed from 27 Dec 2018 to 2 Jan 2019.
- 08 Jan 2018 Status changed from not yet recruiting to recruiting.